[Experience with lamictal in the treatment of outpatients with resistant epilepsy].
The article summarizes the results of lamictal treatment in 93 patients with resistant epilepsy. Lamictal was used in a dose of 50-200 mg a day as an auxiliary drug in the treatment with other anticonvulsants. Its therapeutic efficacy was analyzed in relation to the form of epilepsy, the type of seizures, dosage of lamictal duration of therapy, and as patients' sex, age, and social activity. In the total group, 17.2% of the patients have remissions, in 48.4% the frequency of seizures frequency was reduced (> 50%) and 34.4% of the patients exhibited a less pronounced effect (< 50%). When combining lamictal and valproates, the best results were obtained in generalized seizures, especially in idiopathic generalized epilepsy, and in young and middle-age female patients with active social functioning.
Perunova
N Iu
NIu
Sorokina
E V
EV
Shershever
A S
AS
D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014227:Triazines / Q000008:administration & dosage / Q000627:therapeutic use*
D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine